Matching trials
2,411 results
- ReFOCUS1Independent statistical analysis of Reducing Frailty for Older Cancer Survivors Using Supplements: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04553666).
- Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement: Complete Statistical AnalysisIndependent statistical analysis of Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment: Complete Statistical AnalysisIndependent statistical analysis of Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00288886).
- Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Relative Bioavailability Study of Ropinirole Implants in Parkinson’s Patients on L-Dopa Switched From Oral Ropinirole: Complete Statistical AnalysisIndependent statistical analysis of Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- RELATIVITY-047Independent statistical analysis of RELATIVITY-047, evaluating relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma, including trial design, progression-free survival, statistical methodology, interpretation, and limitations.
- RELEASEIndependent statistical analysis of PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Relieving Acute Pain (RAP) Study: A Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Relieving Acute Pain (RAP) Study: A Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03426137).
- RESISTIndependent statistical analysis of Aspirin Resistance and Percutaneous Coronary Intervention (PCI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01103440).
- RestoreIndependent statistical analysis of RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02090114).
- REVEALIndependent statistical analysis of Evaluation of AMG 714 for Vitiligo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04338581).
- REVELUTIONIndependent statistical analysis of RElugolix VErsus LeUprolide Cardiac Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05320406).
- REVERCEIndependent statistical analysis of the REVERCE phase 2 trial evaluating regorafenib with cetuximab or panitumumab-based treatment in colorectal cancer, including trial design, time-to-event endpoints, log-rank methodology, reported P-values, safety, and statistical interpretation.
- REVIRAL 1Independent statistical analysis of A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.: primary endpoint results, effect estimate with confidence interval, sample-size…
- RIGHT ChoiceIndependent statistical analysis of the randomized phase 2 RIGHT Choice trial of ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast…
- RISE-IIPComplete statistical analysis of RISE-IIP, the randomized phase 2 trial of riociguat versus placebo in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias.
- RISE-MIndependent statistical analysis of Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03634800).
- ROCKETIndependent statistical analysis of A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- ROXI-VTE IIIndependent statistical analysis of A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants: primary endpoint results, effect estimate with confidence interval, sample-size…
- RSLV-132Independent statistical analysis of A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03247686).
- RSV OA=ADJ-023Independent statistical analysis of A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant…
- RSVHRIndependent statistical analysis of A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- RTOG 0417Independent statistical analysis of RTOG 0417, a phase 2 single-group trial of bevacizumab, radiation therapy, and cisplatin in patients with previously untreated locally advanced cervical cancer.
- RTOG 0424Independent statistical analysis of RTOG 0424, evaluating temozolomide and radiation therapy in patients with gliomas, including trial design, time-to-event endpoints, hazard ratios, statistical methods, and interpretation.
- RVD LiteIndependent statistical analysis of Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01782963).
- RVDDIndependent statistical analysis of Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SADHART-CHFIndependent statistical analysis of Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SALPIndependent statistical analysis of Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- SAR-COVIDIndependent statistical analysis of SAR-COVID (NCT04357808), a randomized phase 2 trial evaluating subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection.
- SayWhenIndependent statistical analysis of Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- SCNSL1Independent statistical analysis of High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SCOUTA detailed statistical analysis of the SCOUT phase 1/2 trial of larotrectinib in children with tumors harboring NTRK fusion, including trial design, endpoints, planned analysis, statistical methodology, interpretation, and limitations.
- SEASONIndependent statistical analysis of the SEASON trial evaluating the safety, tolerability, and immunogenicity of motavizumab after dosing for a second season in children.
- SEJIndependent statistical analysis of Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03047473).
- SELECTSUNRISEIndependent statistical analysis of A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and…
- SERENA-2Independent statistical analysis of A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative…
- Sert2Independent statistical analysis of A Trial of Sertraline in Young Children With Autism Spectrum Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SHIVAIndependent statistical analysis of the SHIVA randomized phase II trial evaluating therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer.
- SIGNATUREA detailed statistical analysis of the phase 2 SIGNATURE trial evaluating ceritinib in patients with tumors with aberrations in ALK or ROS1, including trial design, RECIST 1.1 endpoints, planned statistical methods, safety,…
- SIGNATUREIndependent statistical analysis of LDE225 for Patients With PTCH1 or SMO Mutated Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02002689).
- SirolimusIndependent statistical analysis of Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SISTErIndependent statistical analysis of Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00064662).
- SKYGGNIndependent statistical analysis of OCS-01 in Treating Inflammation and Pain in Post-cataract Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04130802).
- SKYLINEIndependent statistical analysis of Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SMA-TBIndependent statistical analysis of Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04575519).
- SMA002Independent statistical analysis of A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SNOCATIndependent statistical analysis of SNOCAT, a randomized phase 2/3 trial of sodium nitrite versus placebo for out-of-hospital cardiac arrest, including primary survival results, secondary endpoints, statistical methods, and interpretation.
- SOLEOIndependent statistical analysis of A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- SOM230Independent statistical analysis of Pasireotide LAR in Severe Polycystic Liver Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01670110).